Transcode Total Current Assets from 2010 to 2025

RNAZ Stock  USD 3.35  0.16  5.02%   
Transcode Therapeutics Total Current Assets yearly trend continues to be fairly stable with very little volatility. Total Current Assets are likely to outpace its year average in 2025. Total Current Assets is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. View All Fundamentals
 
Total Current Assets  
First Reported
2010-12-31
Previous Quarter
5.1 M
Current Value
6.6 M
Quarterly Volatility
5.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Transcode Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Transcode Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 55.3 K, Tax Provision of 0.0 or Net Interest Income of 17.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 22.42. Transcode financial statements analysis is a perfect complement when working with Transcode Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Transcode Therapeutics Correlation against competitors.
For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.

Latest Transcode Therapeutics' Total Current Assets Growth Pattern

Below is the plot of the Total Current Assets of Transcode Therapeutics over the last few years. It is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. Transcode Therapeutics' Total Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Transcode Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Current Assets10 Years Trend
Slightly volatile
   Total Current Assets   
       Timeline  

Transcode Total Current Assets Regression Statistics

Arithmetic Mean3,076,550
Geometric Mean709,611
Coefficient Of Variation189.55
Mean Deviation3,859,319
Median214,646
Standard Deviation5,831,725
Sample Variance34T
Range22.5M
R-Value0.52
Mean Square Error26.7T
R-Squared0.27
Significance0.04
Slope633,681
Total Sum of Squares510.1T

Transcode Total Current Assets History

20256.6 M
20245.1 M
20234.5 M
20227.4 M
202122.7 M
2020831.2 K
2019204.5 K

About Transcode Therapeutics Financial Statements

Transcode Therapeutics investors use historical fundamental indicators, such as Transcode Therapeutics' Total Current Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Transcode Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Current Assets5.1 M6.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Transcode Stock Analysis

When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.